FDA to hold public meetings on DTC

Share this article:
The FDA will be seeking comment on the presentation of risk information, the use of certain advertising strategies, comparative DTC promotion and other topics during a public meeting scheduled for Nov. 1 and Nov. 2 in Washington, D.C.
Notice of the meeting was posted in the Federal Register on Sept. 13.
"FDA is interested in hearing whether the indication of a drug or device can be effectively communicated to a lay audience under the confines of DTC promotion," the public notice read. "FDA is also specifically interested in whether paying greater attention to the educational component of an advertisement would help consumers better understand the role drug and device therapy may play in treating the disease."
The agency is also expected to seek comment on whether free samples, coupons and money-back guarantees are promoting undue influence over consumers.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...